30 closest matches · ranked by relevance
Persistent or Recurrent Cutaneous T-Cell Lymphoma
Primary: Lead-In Part: Number of Participants With Dose-limiting Toxicities (DLTs) as Per National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03…
Lymphoma
Primary: Overall Response Rate After 2 Courses of Treatment
Lymphoma, T-Cell
Primary: Objective Response Rate — 8 percentage of patients
Cutaneous T Cell Lymphoma
Primary: The Number of Participants That Tolerated the Maximum Drug Dose — 8; 4 Participants
Mycoses · Sezary Syndrome · Lymphoma, T-Cell, Cutaneous
Primary: Progression-Free Survival (PFS) at 180 Days — 73 percentage of participants
Lymphoma · T-Cell · Cutaneous
Primary: Response Rate — 0; 0; 1; 1 Participants
Cutaneous T-Cell Lymphoma
Primary: Overall Response Rate of Participants Using the Modified Severity-Weighted Assessment Tool (mSWAT) — 16.7; 20.3; 18.5 percentage
Lymphoma · Disorder Related to Bone Marrow Transplantation
Primary: Participant's Response According to Physician's Global Assessment of Clinical Condition (PGA) — 19; 6; 0; 0 participants
Cutaneous T-Cell Lymphoma
Primary: Percentage of Participants With Confirmed Complete Response (CR) or Partial Response (PR) Among Mycosis Fungoides (MF) and Sezary Syndrome (SS) Participants (Response…
Peripheral T-cell Lymphoma · Cutaneous T-cell Lymphoma
Primary: Objective Response Rate (ORR) — 41.2; 31.6 percentage of participants
Cutaneous T-Cell Lymphoma · Mature T-cell Malignancies · Peripheral T-Cell Lymphoma
Primary: Maximum Tolerated Dose (MTD) — 20 mg/day
Peripheral T-cell Lymphoma · Cutaneous T-cell Lymphoma
Primary: Global Composite Response (Skin, Blood, Lymph Nodes)as Determined by Skin Evaluations, Blood Counts and PET/CT Imaging — 260; 260; 232 days
Cutaneous T-cell Lymphoma
Primary: The Percent of Patients (Pts) With Objective Disease Response — 34 Percent of participants
Non-Hodgkin Lymphoma · Mycosis Fungoides
Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects
Cutaneous T Cell Lymphoma · Peripheral T Cell Lymphoma
Primary: Number of Participants With a Response — 17; 28; 8; 5 participants
Lymphoma
Primary: Dose Limiting Toxicity (DLT) — 0; 1; 1 Participants
Lymphoma
Primary: Median Progression-free Survival — 5 months
Lymphoma
Primary: Parts I & II: Number of Participants Experiencing Clinical or Laboratory Adverse Experiences (AE) — 10; 6 participants
T Cell Lymphoma
Primary: Overall Response Rate — 5 participants
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma · Recurrent Mycosis Fungoides/Sezary Syndrome · Stage I Cutaneous T-cell Non-Hodgkin Lymphoma
Primary: MTD of Photodynamic Therapy — 150 J/cm^2
Peripheral T-cell Lymphoma
Primary: Percentage of Participants With a Complete Response According to the International Workshop Response Criteria (IWC) for Non-Hodgkin's Lymphomas (NHL) Assessed by an…
Lymphoma, T-Cell, Cutaneous
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 1; 0; 0; 0 Participants
Lymphoma
Primary: Response to Treatment — 0; 9 participants
T Cell Non-Hodgkin Lymphoma
Primary: Overall Response Rate — 0.0 proportion of participants
Cutaneous T-Cell Lymphoma
Primary: Number of Responders and Non-Responders With a Treatment Response in 3 Treated Lesions as Defined as a ≥50% Improvement in the Composite Assessment of Index Lesion…
Lymphoma, T-Cell, Cutaneous
Primary: Percentage of Patients With Complete or Partial Response as Measured by Change in Lesion Severity Using CAILS (Composite Assessment of Index Lesion Severity) — 27; 0…
Cutaneous T Cell Lymphoma
Primary: Number of Participants Reported Overall Response (Complete and Partial) of Target Treated Lesions Based on Modified Composite Assessment of Index Lesion Severity…
Anaplastic Large Cell Lymphoma, ALK-Negative · Anaplastic Large Cell Lymphoma, ALK-Positive · Hepatosplenic T-Cell Lymphoma
Primary: Maximum Tolerated Dose (MTD) of Lenalidomide and CHOEP — 10 milligrams
Recurrent Mantle Cell Lymphoma
Primary: Overall Response Rate (Complete and Partial Responses) as Defined by the International Workshop Criteria — 62.5; 52.4 percentage of patients
Refractory Cutaneous T-cell Lymphoma
Primary: Number of Participants With Tumor Response (Complete Response [CR], Clinical Complete Response [CCR], and Partial Response [PR]) in up to 5 Index Lesions as Determined…